newsfilter
← Latest News
GlobeNewswire·

CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

  • CalciMedica's management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 9:30 a.m. ET.
  • A live webcast will be available via the "IR Events and Presentations" section of the company's website, with a replay archived for 90 days.
  • The company develops CRAC channel inhibition therapies for inflammatory, immunologic, & cardiopulmonary diseases.
  • The pipeline includes zegocractin (Auxora™) for IV use, evaluated in over 350 patients for pulmonary hypertension & acute pancreatitis.
  • A Phase 1b proof-of-concept trial for pulmonary hypertension & a Phase 2b trial for acute pancreatitis are planned for Auxora.
  • CM5480 is an oral CRAC channel inhibitor for pulmonary hypertension with an IND submission anticipated in mid-2027.